SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...

A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate cancer will benefit from adding hormone therapy to radiation after surgery - the ...

Distinguishing cancer cells from healthy cells is a central challenge in cancer treatment. Ideal therapies selectively kill cancer cells while leaving healthy cells healthy and able to perform their ...

The core foundation of precision medicine, and in turn, precision oncology, is a personalized approach to treatment that focuses on targeting specific molecular features that impact how cancer cells ...

People assigned female at birth can't get prostate cancer because they don't have a prostate gland. However, women can get a rare type of cancer that develops in the Skene's glands, a pair of organs ...

CTC and AR-V7 analysis in the ECOG-ACRIN 8153 (CHAARTED2) randomized trial: Abiraterone (Abi) with or without cabazitaxel (Abi-Cabazi) in extensive mCRPC following docetaxel. This is an ASCO Meeting ...

Genomic alterations and pathologic responses to neoadjuvant androgen receptor pathway inhibitor (ARPI) doublets vs docetaxel triplets in the Genomic Umbrella Neoadjuvant study (GUNS). This is an ASCO ...

Neighborhood disadvantage is associated with greater expression of stress-related genes that are linked to more aggressive prostate cancer. Men from disadvantaged neighborhoods have higher expression ...

A five-year study on men that had just the cancerous portion of their prostate glands destroyed shows that the procedure averted cancer recurrence in most patients while preserving urinary and sexual ...